According to clinical reports, both the high-affinity anti-EpCAM antibodies, ING-1 and 3622W94, cause acute pancreatitis, while the other low-affinity anti-EpCAM antibodies, adecatumumab and edrecolomab, produced neither pancreatic side-effects nor any anti-tumor effects [14]. The gene discussed is EPCAM; the disease is acute pancreatitis.